TABLE 3.
Most common treatment pathways
| First | Second | Third | n | % of 22 288 |
|---|---|---|---|---|
| Levetiracetam | 9663 | 43% | ||
| Gabapentin | 2231 | 10% | ||
| Valproate | 1125 | 5% | ||
| Phenytoin | 867 | 4% | ||
| Levetiracetam | Gabapentin | 857 | 4% | |
| Lamotrigine | 510 | 2% | ||
| Levetiracetam | Valproate | 462 | 2% | |
| Levetiracetam | Lamotrigine | 381 | 2% | |
| Topiramate | 284 | 1% | ||
| Lacosamide | 272 | 1% | ||
| Phenytoin | Levetiracetam | 269 | 1% | |
| Levetiracetam | Lacosamide | 240 | 1% | |
| Levetiracetam | Phenytoin | 235 | 1% | |
| Oxcarbazepine | 210 | 1% | ||
| Carbamazepine | 178 | 1% | ||
| Gabapentin | Levetiracetam | 169 | 1% | |
| Gabapentin | Pregabalin | 157 | 1% | |
| Valproate | Levetiracetam | 144 | 1% | |
| Pregabalin | 140 | 1% |
Only those comprising at least 1% of all pathways are shown here. Each row represents a pathway, and this table displays how many beneficiaries had a sequence of antiseizure medication fill following each pathway.